Abstracts tagged "Economics"

Abstract Number: 0585 • ACR Convergence 2020
Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
Jan Sorensen¹, Mette Aadahl², Merete Hetland³, Bente Appel Esbensen⁴ and Tanja Thomsen², ¹Healthcare Outcomes Research Centre, Dublin, Dublin, Ireland, ²Centre for Clinical Research and Prevention, Frederiksberg, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ⁴University of Copenhagen, Glostrup, Hovedstaden, Denmark
Background/Purpose: The “Joint Resources – Sedentary Behaviour” randomised controlled trial (RCT) (1,2,3) aimed to reduce sedentary behaviour in patients with rheumatoid arthritis (RA) by means…
Abstract Number: 0600 • ACR Convergence 2020
Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation
Daniel DeMizio¹, Guojing Wu², Ying Wei², Joan Bathon³ and Runsheng Wang⁴, ¹Columbia University Irving Medical Center, Division of Rheumatology, Staten Island, NY, ²Columbia University Mailman School of Public Health, Department of Biostatistics, New York, NY, ³Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁴Columbia University Irving Medical Center, Division of Rheumatology, New York, NY
Background/Purpose: There is growing evidence that both the prevalence of gout and its burden on healthcare costs has increased over recent decades. It has been…
Abstract Number: 0602 • ACR Convergence 2020
Labor Impact of SARS-COV-2 Pandemic in Argentine Rheumatologists
Scarafia Santiago¹, Emilio Buschiazzo², María Victoria Martire³, César Graf⁴ and Rodrigo Garcia Salinas⁵, ¹Hospital Municipal "San Cayetano", Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Señor del Milagro, Salta., Salta, Salta, Argentina, ³Instituto Médico Platense, La Plata, La Plata, Buenos Aires, Argentina, ⁴Sociedad Argentina de Reumatología, Paraná, Entre Rios, Argentina, ⁵Hospital Italiano La Plata, La Plata, Argentina
Background/Purpose: The novel coronavirus SARS2-COV-2 has precipitated the present outbreak of COVID-19, the worldwide spread has strong impact on general population and on healthcare workers.…
Abstract Number: 0616 • ACR Convergence 2020
Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
Ashley White¹, Trevor Faith¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex, multifactorial disease with heterogeneous presentation. Disease activity – the number and severity of symptoms – can be…
Abstract Number: 0756 • ACR Convergence 2020
Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive
Joe Zhuo¹, Manasi Suryavanshi¹, Lawshia Priya², Vadim Khaychuk¹, John Vaile¹, Jing Cui³, Nancy Shadick⁴ and Michael Weinblatt³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Mu-Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: A strong genetic association between HLA-DRB1 alleles containing the shared epitope (SE) and RA has been described.1 The SE has been associated with ACPA…
Abstract Number: 1880 • ACR Convergence 2020
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵ and Kaleb Michaud⁶, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…
Abstract Number: 360 • 2019 ACR/ARP Annual Meeting
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth ² and Peter Donovan ³, ¹University of Queensland, Brisbane, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Queensland, HERSTON, Australia
Background/Purpose: Prophylaxis of acute gout flares when commencing urate lowering therapy is recommended by international guidelines. Whether this is a cost-effective intervention is currently unknown.…
Abstract Number: 1113 • 2019 ACR/ARP Annual Meeting
Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool
Hua Wei¹, Anbin Huang ², Li Luo ³, Fen Wang ⁴, Qin Li ⁵, Hong Zhang ⁶, Yong Wang ⁷, Peng Ji ³, Yanping Zhao ⁸, LingXun Shen ⁹, Zhengang Wang ¹⁰, Feng Wei ¹¹, Tong Xie ¹², Xiaohan Wang ¹³, Huifang Guo ¹⁴, Qiang Shu ¹⁵, Xiangyuan Liu ¹⁶, Rong Du ¹⁷, Anbing Zhang ¹⁸, Fang Qin ¹⁹, Bing Wu ²⁰, Yuhua Jia ²¹, Hui Xiao ²², Fei Xiao ²³ and Fengchun Zhang ²⁴, ¹Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ²Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technolog, Han Wu, Hubei, China (People's Republic), ³The first affiliated hospital of xinjiang medical university, Urumchi, China (People's Republic), ⁴First Affiliated Hospital of Medical University Of Anhui, Hefei, Anhui, China (People's Republic), ⁵The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (People's Republic), ⁶The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ⁷The first Hospital Affiliated to AMU (Southernwest Hospital), Chongqing, China (People's Republic), ⁸First Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), ⁹Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹⁰TongRen hospital,Capital University, Bei Jing, China (People's Republic), ¹¹Jiangmen Central Hospital Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China (People's Republic), ¹²Affiliated hospital of Guangdong medical University, Zhanjiang, Guangdong, China (People's Republic), ¹³Anyang district hospital, Fuyang, Hainan, China (People's Republic), ¹⁴The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic), ¹⁵Qilu Hospital of Shandong University, Jinan, China (People's Republic), ¹⁶Peking University Third Hospital, Beijing, China (People's Republic), ¹⁷Union hospital affiliated to huazhong university of science and technology, Wuhan, China (People's Republic), ¹⁸Xiangyang city center hospital, Xiangyang, China (People's Republic), ¹⁹The first affiliated hospital of guangxi medical university, Nanning, China (People's Republic), ²⁰Shanghai Gothic Internet Technology Co., Ltd, Shanghai, China (People's Republic), ²¹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²²Shanghai Gothic Internet Technology Co., Ltd, shanghai, Shanghai, China (People's Republic), ²³Shanghai Gothic Internet Technology Co., Ltd., shanghai, China (People's Republic), ²⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Without efficient primary medical care and follow-up system in China, patients can choose any hospital or doctor they like in seeking medical care. As…
Abstract Number: 1174 • 2018 ACR/ARHP Annual Meeting
Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
Jennie H. Best and Jinglan Pei, Genentech, Inc., South San Francisco, CA
Background/Purpose: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 1757 • 2018 ACR/ARHP Annual Meeting
An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis
Scott Doyle¹, Emily Moss², Louise Hartley², Chris Knight², Judith Bell², Outi Ahdesmäki² and Maebh Kelly³, ¹Value Evidence and Outcomes, GlaxoSmithKline, London, United Kingdom, ²RTI Health Solutions, Manchester, United Kingdom, ³Pope Woodhead, London, United Kingdom
Background/Purpose: To better understand the available economic evaluations in eosinophilic granulomatosis with polyangiitis (EGPA), a systematic literature review was undertaken. The primary objective of this…
Abstract Number: 2183 • 2018 ACR/ARHP Annual Meeting
Access to Prescription Drugs in Canada: Results from an Online Survey
Nick Bansback^1,2,3, Cheryl L. Koehn⁴, Judy Chiu⁵, Melanie Mulder⁶ and Linda Li¹, ¹Arthritis Research Canada, Richmond, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁴Arthritis Consumer Experts, Vancouver, BC, Canada, ⁵Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁶St Paul's Hospital, Vancouver, BC, Canada
Background/Purpose: Prescription medications are an important treatment option for patients living with arthritis. However, patients may often not have access to certain medications they hear…
Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Jennie H. Best¹, Amanda Kong², David Smith², Ibrahim Abbass¹ and Margaret Michalska¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Bethesda, MD
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…
Abstract Number: 133 • 2017 ACR/ARHP Annual Meeting
Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden
Anders Gülfe¹, Tor Olofsson¹, Jonas K Söderling², Martin Neovius² and Johan K Wallman¹, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure…
Abstract Number: 199 • 2017 ACR/ARHP Annual Meeting
Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study
Natalie McCormick^1,2, Carlo Marra³ and J. Antonio Avina-Zubieta⁴, ¹Arthritis Research Canada, Richmond, BC, Canada, ²Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, ³School of Pharmacy, University of Otago, Dunedin, New Zealand, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Little is known about the healthcare costs of systemic lupus erythematosus (SLE) patients in the years leading up to SLE diagnosis. We estimated the…
Abstract Number: 224 • 2017 ACR/ARHP Annual Meeting
Patterns of Methotrexate Use in African Countries with Low Versus Medium/High Human Development Index: Preliminary Results of Semi-Structured Interviews
Carol A Hitchon¹, Yan Liu², Steven Shi³, Girish M Mody⁴, Candace H. Feldman⁵, Michael Weinblatt⁶ and Ines Colmegna⁷, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montreal, QC, Canada, ³University de Montreal, Montreal, QC, Canada, ⁴Dept of Rheumatology, University of Kwa Zulu-Natal, Durban, South Africa, ⁵Brigham and Women’s Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada
Background/Purpose: Methotrexate (MTX) is standard therapy for rheumatoid arthritis (RA) and also used to treat other rheumatic diseases. Existing guidelines for RA treatment/ MTX use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].